Opinion
Video
Jason Hafron, MD, on PSMA-PET in oligometastatic disease
Author(s):
Key Takeaways
- PSMA-PET imaging enhances tumor localization, enabling targeted treatment strategies in oligometastatic prostate cancer management.
- Metastasis-directed therapy (MDT) can be applied with or without ARPIs and ADT, offering potential hormone-free treatment options.
“Time will tell as we move forward, but it has allowed us to use MDT, with or without ADT and ARPIs, to potentially look at hormone-free treatments,” says Jason M. Hafron, MD, CMO.
In this video, Jason M. Hafron, MD, explains how PSMA-PET has enabled the use of more targeted treatment approaches in the management of oligometastatic prostate cancer. Hafron is the chief medical officer and medical director of clinical research of Michigan Institute of Urology.
Video Transcript:
PSMA-PET is very helpful in the oligometastatic space. It identifies tumor location. And in my practice, we've identified disease where we could offer radiation therapy in combination with ARPI or without ARPI and ADT, so it allows us to do stereotactic. I've definitely developed a closer relationship with our rad oncs. And before, where we would just consider systemic disease, systemic disease, we've looked at, can we do metastasis-directed therapy and apply and look at the disease differently. The data on metastasis-directed therapy is still developing. It's not fully mature, but in our practice, we found it very impactful. Time will tell as we move forward, but it has allowed us to use MDT, with or without ADT and ARPIs, to potentially look at hormone-free treatments.
This transcript was AI generated and edited by human editors for clarity.
